Related Experiment Video
Updated: May 19, 2026

Knockdown of FAM83A to Verify Its Role in Cervical Cancer Cell Growth and Cisplatin Sensitivity
Published on: February 9, 2024
FAM83A and FAM83B: candidate oncogenes and TKI resistance mediators
1Division of Hematology/Oncology, Virginia Commonwealth University Health Science Center, Richmond, Virginia 23229, USA. stgrant@vcu.edu
Abstract:
The growth and survival of tumor cells can depend upon the expression of a single oncogene, and therapeutically targeting this oncogene addiction has already proven to be an effective approach in fighting cancer. However, it is also clear that cancer cells can adapt and become resistant to therapy through compensatory activation of downstream pathways that relieve the cell of its addicted phenotype. In this issue of the JCI, two groups--Lee et al. and Cipriano et al.--identify two related candidate oncogenes that might both contribute to therapeutic resistance to tyrosine kinase inhibitors (TKIs). If validated, this information could help to identify new targets for therapeutic interventions in breast cancer and possibly other cancers and may also assist in the development of strategies designed to overcome resistance to currently available TKIs.
Insights
Cancer cells can develop resistance to targeted therapies by activating new pathways. This study identifies potential oncogenes that may drive resistance to tyrosine kinase inhibitors (TKIs), offering new therapeutic targets.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- Tumor cell growth is often dependent on specific oncogenes, a concept known as oncogene addiction.
- Cancer cells can develop resistance to targeted therapies by activating alternative signaling pathways.
- Tyrosine kinase inhibitors (TKIs) are a class of drugs used in cancer therapy.
Discussion:
- Two independent studies identify related candidate oncogenes potentially involved in TKI resistance.
- These oncogenes may help cancer cells overcome their dependence on specific signaling pathways.
- Understanding these mechanisms is crucial for overcoming therapeutic resistance.
Key Insights:
- Identification of novel candidate oncogenes contributing to therapeutic resistance.
- Potential role of these oncogenes in breast cancer and other malignancies.
- Provides a basis for developing strategies to combat TKI resistance.
Outlook:
- Further validation of these candidate oncogenes is required.
- Potential for new therapeutic targets to overcome drug resistance.
- May inform the development of combination therapies or novel treatment strategies.
Related Concept Videos
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Mitogens and the Cell Cycle
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

